Discovery and Validation of AMD Biomarkers for Progression Using Deep Learning
Discovery and Validation of AMD Biomarkers for Progression Using Deep Learning
批准号:
9807978
负责人:
Zhihong HU
金额:
$23.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-01 至 2021-07-31
关键词:
3-DimensionalAge related macular degenerationAlgorithmsArchitectureArtificial IntelligenceAtrophicBackBiological MarkersBlindnessClassificationClinicClinicalClinical ResearchClinical TrialsConsensusConsumptionDataData SetDepositionDevelopmentDiseaseDrusenEarly InterventionEarly intervention trialsElderlyFutureImageIndividualLearningLesionMachine LearningManualsMapsMeta-AnalysisMonitorNeuronsNonexudative age-related macular degenerationOptical Coherence TomographyOutcomeOutcome MeasurePatientsPhenotypeProcessReadingResearchResearch PersonnelResidual stateRiskRisk FactorsScanningSpecific qualifier valueStagingStaging SystemSystemTechniquesTherapeutic TrialsTimeTrainingValidationVisitWorkbaseclinical practicedeep learningdeep neural networkeffective therapyfollow-upgeographic atrophyhigh riskimaging Segmentationimprovedmultidisciplinarynovelnovel therapeuticsprimary outcomeprognosticresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness among elderly individuals.
Currently there are no proven effective therapies for treatment of advanced non-neovascular AMD, termed
geographic atrophy (GA). Earlier intervention may be preferable, but this would require identification of those
individuals with the highest risk for progression to atrophy. Over the last two decades, various studies
including ours have identified several optical coherence tomography (OCT)-based factors that appear to
associate with a higher risk for AMD progression.
The central hypothesis of this proposal is that a deep learning - artificial intelligence (AI) construct can
objectively and automatically learn and quantify the most important risk factors, yielding a better prediction of
AMD progression risk than current subjectively specified features. In this proposal, we will first develop an AI-
based system to automatically identify the “subjectively-specified” high risk factors based on individual spectral
domain (SD) OCT 2D scans, and to automatically segment GA (the end-stage outcome variable of AMD) in
OCT 2D en face maps. Subsequently, as a proof-of-concept study of our hypothesis, we will apply an AI-based
“reverse learning” approach to objectively learn and identify AMD high risk factors in longitudinal OCT data.
To achieve these objectives, we will pursue the following specific aims:
Aim 1: Develop and validate an AI approach to classify individual OCT 2D scans as containing or not
containing the pre-specified risk factor(s). In our previous work, we manually identified the presence or
absence of the pre-specific high-risk factors and assigned to a risk score based on the entire OCT volume. Such
approach was time consuming and not precise. In this proposal, an AI algorithm will be applied to detect the
high risk factors from individual OCT scans. Hence, the precision of the scoring system can be greatly
enhanced with high computational complexity.
Aim 2: Develop and validate an AI approach to segment GA lesions from 2D OCT en face maps. For the OCT
volumes having atrophy, we will perform the GA segmentation from the choroidal hypertransmission-resulted
en face map using the multi-scale CNNs.
Aim 3: Develop and validate an AI “reverse learning” approach to objectively identify the high risk factors using
longitudinal OCT data. The “reverse learning” will be based on the multiple CNNs, followed by de-
convolutional networks to identify the high risk factors objectively. Our previous scoring system will possibly
be refined and optimized by the potential inclusion (or substitution) of novel risk factors derived from our
objective AI approaches.
The work in this proposal will be performed retrospectively in SD-OCT images from the image data pool that
the multi-PI Sadda has aggregated over years as the director of the Doheny image reading center.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Artificial Intelligence for Assessment of Stargardt Macular Atrophy
-
批准号:9895214
-
项目类别:
-
资助金额:$23.55万
-
财政年份:2020
-
负责人:Zhihong HU
-
依托单位:
Artificial Intelligence for Assessment of Stargardt Macular Atrophy
-
批准号:10077550
-
项目类别:
-
资助金额:$19.04万
-
财政年份:2020
-
负责人:Zhihong HU
-
依托单位:
海外基金